Valeant Pharmaceuticals International Inc. (NYSE:VRX) was down 2.2% during mid-day trading on Tuesday . The company traded as low as $26.33 and last traded at $26.51, with a volume of 10,963,434 shares. The stock had previously closed at $27.10.

A number of equities research analysts have issued reports on VRX shares. Wells Fargo & Co. reiterated an “underperform” rating and issued a $27.50 target price (down previously from $29.00) on shares of Valeant Pharmaceuticals International in a research report on Friday, May 27th. BMO Capital Markets reiterated a “hold” rating and issued a $44.00 target price on shares of Valeant Pharmaceuticals International in a research report on Friday, May 27th. S&P Equity Research reiterated a “buy” rating on shares of Valeant Pharmaceuticals International in a research report on Sunday, May 29th. Susquehanna reiterated a “hold” rating and issued a $105.00 target price on shares of Valeant Pharmaceuticals International in a research report on Sunday, May 29th. Finally, Piper Jaffray Cos. reiterated a “sell” rating on shares of Valeant Pharmaceuticals International in a research report on Sunday, May 29th. Six equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. The stock currently has an average rating of “Hold” and a consensus target price of $56.09.

The company has a 50 day moving average of $27.65 and a 200 day moving average of $29.13. The firm’s market capitalization is $9.15 billion.

This story is the sole property of American Banking News and it was originally published by American Banking News. If you are reading this story on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. The original version of this article is available at http://www.americanbankingnews.com/2016/09/20/valeant-pharmaceuticals-international-inc-vrx-stock-price-down-2-2.html

Valeant Pharmaceuticals International (NYSE:VRX) last released its quarterly earnings results on Tuesday, August 9th. The specialty pharmaceutical company reported $1.40 EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $1.48 by $0.08. Valeant Pharmaceuticals International had a negative net margin of 9.29% and a positive return on equity of 46.59%. The business earned $2.42 billion during the quarter, compared to analyst estimates of $2.47 billion. During the same quarter last year, the company posted $2.14 earnings per share. The company’s revenue was down 11.4% on a year-over-year basis. On average, equities analysts expect that Valeant Pharmaceuticals International Inc. will post $6.53 earnings per share for the current year.

In other Valeant Pharmaceuticals International news, Director Argeris N. Karabelas purchased 4,000 shares of the firm’s stock in a transaction that occurred on Thursday, August 11th. The shares were acquired at an average cost of $24.65 per share, for a total transaction of $98,600.00. Following the completion of the purchase, the director now owns 20,726 shares of the company’s stock, valued at approximately $510,895.90. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. 16.37% of the stock is currently owned by corporate insiders.

Institutional investors have recently added to or reduced their stakes in the stock. Top Ace Asset Management Ltd purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth about $2,630,000. Commonwealth Equity Services Inc increased its stake in shares of Valeant Pharmaceuticals International by 103.3% in the first quarter. Commonwealth Equity Services Inc now owns 14,721 shares of the specialty pharmaceutical company’s stock worth $387,000 after buying an additional 7,481 shares during the last quarter. Virginia Retirement System purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth about $1,685,000. IFP Advisors Inc increased its stake in shares of Valeant Pharmaceuticals International by 12.7% in the first quarter. IFP Advisors Inc now owns 171,941 shares of the specialty pharmaceutical company’s stock worth $4,522,000 after buying an additional 19,369 shares during the last quarter. Finally, CQS Cayman LP purchased a new stake in shares of Valeant Pharmaceuticals International during the first quarter worth about $2,630,000. Institutional investors and hedge funds own 63.60% of the company’s stock.

About Valeant Pharmaceuticals International

Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).

5 Day Chart for NYSE:VRX

Receive News & Ratings for Valeant Pharmaceuticals International Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals International Inc. and related companies with MarketBeat.com's FREE daily email newsletter.